Provided by Tiger Trade Technology Pte. Ltd.

Acorda Therapeutics

0.6610
0.0000
Volume:- -
Turnover:296.49K
Market Cap:821.03K
PE:0.00
High:0.6610
Open:0.6610
Low:0.6610
Close:0.6610
52wk High:24.20
52wk Low:0.6116
Shares:1.24M
Float Shares:1.22M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-203.5861
EPS(LYR):-203.5862
ROE:-23.68%
ROA:-5.77%
PB:-0.01
PE(LYR):0.00

Loading ...

Company Profile

Company Name:
Acorda Therapeutics
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.